Myriad to license patchomiqs you have the technological platform for prostate cancer

Washington (DPA -AFX) – Myriad Genetics (MyGN) and PHATHOMIQ have concluded a strategic collaboration for Myrid to license exclusively Pathomiq_prad, Pathomiqs you have the technological platform for prostate cancer in the United States. Adding pathomiq_rd to numerous oncological solutions allows Myriad to offer urologist and radiation oncologists with molecular test solutions and AI-alimetated to inform decisions both before treatment, at the time of biopsy, for active surveillance and after surgery or treatment with treatment with radiation.

Myriad plans to launch its first prostate clinical cancer test led by AI later this year.

For more such health news, visit rttnews.com.